As Seen In
Vancouver Biotech Receives U.S. Patent for Hair Regeneration Technology
12 years ago
Apr 18, 2013 
By Emma Crawford, Thu Apr 18, 2013 10:53am PST
Vancouver biotech RepliCel Life Sciences Inc. (OTCQB:REPCF)(CNSX:RP) has received a United States patent for its technology related to hair regeneration, the company announced this morning.
The company’s hair restoration procedure involves taking a small biopsy from the back of a patient’s scalp and preparing populations of “dermal sheath cup cells” that are then used to treat patients with pattern hair loss.
“The allowance of our first U.S. patent is a major achievement for our business as the United States represents the largest current market for hair restoration procedures, conservatively estimated at over $1.3 billion annually,” said David Hall, CEO of RepliCel. “The market for a permanent, non-invasive procedure like RepliCel’s is clearly significant.
“If you factor in the still-untouched market of hair loss in women, the total patients for RepliCel’s treatment would expand even further.”
The company already has patents in Australia and the European Union.
Link to article: http://www.biv.com/replicel-us-patent-issue-notification
Email: ecrawford@biv.com
Twitter: @EmmaCrawfordBIV
by Topic
DISCLAIMER:
The information in these press releases is historical in nature, has not been updated, and is current only to the date indicated in the particular press release. This information may no longer be accurate and therefore you should not rely on the information contained in these press releases. To the extent permitted by law, RepliCel Life Sciences Inc. and its employees, agents and consultants exclude all liability for any loss or damage arising from the use of, or reliance on, any such information, whether or not caused by any negligent act or omission.
THIRD PARTY CONTENT
Please note that any opinion, estimates or forecasts made by the authors of these statements are theirs alone and do not represent opinions, forecasts or predictions of RepliCel Life Sciences Inc. or its management. RepliCel Life Sciences Inc. does not, by its reference or distribution of these links imply its endorsement of, or concurrence with, such information, conclusions or recommendations.